India’s First Intra-Nasal Vaccine for COVID-19

Published on September 07, 2022
Current Context: The Central Drugs Standard Control Organisation (CDSCO) approved Bharat Biotech's ChAd36-SARS-CoV-S COVID-19 recombinant nasal vaccine.
India’s First Intra-Nasal Vaccine for COVID-19
  • It will be used in cases of emergency for the 18+ age group.
  • The vaccine – iNCOVACC – is stable at 2-8 degrees Celcius for easy storage and distribution.
  • iNCOVACC is a recombinant replication-deficient adenovirus vector (Chimpanzee Adenovirus Vectored) vaccine with stabilized spike protein.
  • The Phase I, II, and III trials of the needle-free vaccine, iNCOVACC, have already been completed.
  • iNCOVACC has been specially formulated to allow intra-nasal delivery through nasal drops and could appeal to vaccine-hesitant people.
  • Bharat Biotech International Limited is a multinational biotechnology company in India that was founded in 1996 and has its headquarters in Hyderabad. Dr. Krishna Ella is the Chairperson and Managing Director of Bharat Biotech. The only indigenous "needle" vaccine of India, Covaxin, has been developed by Bharat Biotech.


Q.1 The needle-free nasal vaccine iNCOVACC for COVID-19 has been manufactured by?
a. Serum Institute of India
b. Pfizer
c. Bharat Biotech
d. Moderna

Can I help you?

ramandeep singh

Hey I am Ramandeep Singh. I am determined to help students preparing for RBI, SEBI, NABARD and IBPS exams. Do you want me to help you ?

Join my class here
    Follow me:
Close Menu
Close Menu